Montag A & Associates Inc. Sells 8,571 Shares of Abbott Laboratories $ABT

Montag A & Associates Inc. lowered its stake in Abbott Laboratories (NYSE:ABT) by 7.9% during the fourth quarter, Holdings Channel reports. The firm owned 99,857 shares of the healthcare product maker’s stock after selling 8,571 shares during the period. Montag A & Associates Inc.’s holdings in Abbott Laboratories were worth $12,511,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of ABT. Harbor Capital Advisors Inc. bought a new position in Abbott Laboratories in the fourth quarter valued at about $27,000. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories in the third quarter valued at about $31,000. Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories in the third quarter valued at about $33,000. Finally, Copia Wealth Management bought a new position in Abbott Laboratories in the third quarter valued at about $38,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $89.51 on Friday. The stock has a market cap of $155.90 billion, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 1.49 and a beta of 0.66. The company has a current ratio of 1.39, a quick ratio of 1.18 and a debt-to-equity ratio of 0.56. The stock’s 50-day moving average is $104.33 and its 200-day moving average is $116.09. Abbott Laboratories has a 1-year low of $89.14 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 70.59%.

Analyst Ratings Changes

A number of research firms have issued reports on ABT. BTIG Research reiterated a “buy” rating and issued a $131.00 target price on shares of Abbott Laboratories in a research report on Monday, April 27th. Mizuho decreased their target price on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Piper Sandler decreased their target price on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Jefferies Financial Group decreased their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Finally, Wells Fargo & Company decreased their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $119.43.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders acquired 22,200 shares of company stock valued at $2,215,100 and sold 3,055 shares valued at $353,097. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.